Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.

ABSTRACT:

Purpose

Vascular endothelial growth factor (VEGF) inhibitors have produced demonstrable but limited benefit for various cancers. One mechanism of resistance includes revascularization, secondary to upregulation of alternative pro-angiogenic platelet-derived growth factor receptor and fibroblast growth factor receptor pathways. Nintedanib is an oral, triple kinase inhibitor that blocks these pathways and may improve anti-tumor activity by overcoming resistance to anti-VEGF therapies. The primary objective of this first in-human study was to evaluate the safety and tolerability of nintedanib in combination with bevacizumab.

Methods

Patients were treated with escalating doses of nintedanib (150 mg or 200 mg oral twice daily) and bevacizumab (15 mg/kg once intravenously every 3 

SUBMITTER: Paluri R 

PROVIDER: S-EPMC6490179 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature